Please login to the form below

Not currently logged in
Email:
Password:

Targovax strengthens board of directors

Catherine Wheeler joins from Acetylon Pharmaceutical

Clinical stage company Targovax has added to its board of directors with the appointment of Catherine Wheeler.

Most recently, Wheeler served Acetylon Pharmaceutical as chief medical officer and prior to that she held progressively senior clinical and business development roles at Roche, AstraZeneca and Parexel.

Patrick Vink, chairman of the board at Targovax, said: “We are delighted to welcome Catherine, she brings extensive international oncology expertise and insights that will further strengthen the board.

“She has had a long and distinguished career and has significant experience of bringing innovative oncology treatments to market that will be invaluable as we continue to progress the clinical development of our novel and complementary portfolio of cancer immunotherapies.”

18th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...
International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...

Infographics